Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers
Journal of Clinical Apheresis · 2022-08 · 37 (4) · 360-366
DOI: 10.1002/jca.21982 ↗At a glance
Journal article in Journal of Clinical Apheresis, published online on 2022-03-30. Written by Thilo Gambichler and 5 co-authors. Institution: Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany. Major MEDLINE topics: Mycosis Fungoides, Photopheresis, Skin Neoplasms. Cited 8 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Systemic immune‐inflammatory biomarkers (SIIBs) have not been studied in mycosis fungoides (MF) patients undergoing extracorporeal photopheresis (ECP).
Objective
The objective was to determine whether recently proposed SIIBs are suitable to predict ECP treatment outcome and overall prognosis of patients with MF.
Methods
Twenty‐nine MF patients were retrospectively evaluated who had undergone ECP. SIIBs included neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio, lymphocyte‐to‐monocyte ratio, and pan‐immune‐inflammation value.
Results
Lymphocyte count ( P = .021), CD4+/CD8+ cells ( P = .00006), CD4+/CD56+ NK cells ( P = .00008), and LDH levels ( P = .0041) significantly declined after 6‐month ECP. We could not detect significant cutoff values for baseline SIIBs capable of predicting advanced disease, overall response to 6‐month ECP, or 5‐year lymphoma‐specific (LS) survival ( P > .05). Circulating baseline counts of CD4+/CD7‐ cells (cutoff: ≤ 12.2; P = .010) and CD4+/CD26‐ cells (cutoff: ≤ 19.5; P < .0001) significantly predicted ECP treatment response after 6 months. Moreover, CD4+/CD8+ ratio (cutoff: > 1.34; P = .045) and increased thrombocyte counts (cutoff: >259 000; P = .010) were baseline predictors for 5‐year LS death.
Conclusion
ECP appears to be beneficial in early‐stage CTCL as well. Lower percentages of circulating CD4+/CD7‐ and CD4+/CD26‐ lymphocytes at baseline correlate with response to ECP. In this study, however, baseline SIIBs did not appear to serve as suitable biomarkers for the prediction of treatment outcome and LS survival.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
ORCID profiles: Thilo Gambichler
Cite
APA
Gambichler, T., Späth, J., Said, S., Scheel, C. H., Susok, L., & Stranzenbach, R. (2022). Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers. Journal of Clinical Apheresis, 37(4), 360-366. https://doi.org/10.1002/jca.21982
Vancouver
Gambichler T, Späth J, Said S, Scheel CH, Susok L, Stranzenbach R. Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers. Journal of Clinical Apheresis. 2022;37(4):360-366. doi:10.1002/jca.21982
BibTeX
@article{Gambichler2022,
author = {Gambichler, Thilo and Späth, Jan and Said, Shayda and Scheel, Christina H and Susok, Laura and Stranzenbach, Rene},
title = {Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers},
journal = {Journal of Clinical Apheresis},
year = {2022},
volume = {37},
number = {4},
pages = {360--366},
doi = {10.1002/jca.21982}
}
EUVIMED